Cardiovascular Prevention: 2026 Doctor's Guide

What Is Cardiovascular Prevention and Who Needs It?

Cardiovascular prevention means using lifestyle change, medications, or both to stop a first heart attack or stroke (primary prevention) or to prevent a second event in someone who has already had one (secondary prevention). The decision to treat hinges on a quantified 10-year ASCVD risk score, not on symptoms alone.

Who should be screened?

The 2019 ACC/AHA guideline on primary prevention recommends calculating the Pooled Cohort Equations (PCE) 10-year risk score for all adults aged 40 to 79 without pre-existing CVD [1]. A score at or above 7.5 percent generally triggers a clinician-patient "risk discussion" before starting medications. Adults with diabetes, chronic kidney disease, or a family history of premature CVD may warrant treatment at lower thresholds.

Absolute risk categories and what they mean

• Low risk: <5% 10-year ASCVD. Lifestyle modification is the primary tool.
• Borderline risk: 5 to <7.5%. Risk-enhancing factors (LP(a) above 50 mg/dL, hs-CRP above 2 mg/L, ABI <0.9) may tip the decision toward statin therapy [1].
• Intermediate risk: 7.5 to <20%. Statin therapy recommended; coronary artery calcium (CAC) scoring may refine the decision.
• High risk: ≥20%, or established ASCVD. Aggressive multi-drug therapy is standard.

The "treat to target" principle

The 2022 ACC Expert Consensus Decision Pathway specifies LDL-C targets of <70 mg/dL for high-risk and <55 mg/dL for very-high-risk patients [2]. Reaching these targets by any combination of statin plus ezetimibe plus PCSK9 inhibitor is acceptable. The vehicle matters less than the destination.

Statin Therapy: The Cornerstone of Lipid Lowering

Statins remain the most thoroughly studied class in CV prevention. The Cholesterol Treatment Trialists (CTT) Collaboration meta-analysis of 26 trials (N=170,000+) found that each 1 mmol/L reduction in LDL-C cut major vascular events by about 22 percent [3]. That translates to roughly 10 fewer events per 1,000 patients treated over five years at intermediate risk.

High-intensity vs. Moderate-intensity statins

High-intensity regimens (atorvastatin 40-80 mg, rosuvastatin 20-40 mg) lower LDL-C by at least 50 percent. Moderate-intensity regimens (atorvastatin 10-20 mg, rosuvastatin 5-10 mg, simvastatin 20-40 mg) lower LDL-C by 30 to <50 percent [1]. For secondary prevention patients, high-intensity therapy is the default unless tolerability is a concern.

Adding ezetimibe and PCSK9 inhibitors

When statins alone do not reach the LDL-C target, ezetimibe is the standard next step. IMPROVE-IT (N=18,144) showed that adding ezetimibe 10 mg to simvastatin 40 mg after acute coronary syndrome reduced the composite CV endpoint by an additional 6.4 percent relative risk reduction [4]. For patients who still do not reach target, evolocumab (Repatha) or alirocumab (Praluent) lower LDL-C by 50 to 60 percent on top of maximally tolerated statin. FOURIER (N=27,564) showed evolocumab cut the composite of CV death, MI, and stroke by 15 percent [5].

Statin safety and myopathy risk

Serious myopathy occurs in roughly 1 per 10,000 patient-years. Simvastatin 80 mg carries the highest myopathy risk and is no longer recommended for new prescriptions per FDA guidance [6]. Routine CK monitoring is not needed unless the patient is symptomatic.

Blood Pressure Control: Numbers That Save Lives

Hypertension affects about 47 percent of U.S. Adults and is the single largest modifiable risk factor for stroke and MI [7]. The 2017 ACC/AHA hypertension guideline defines hypertension as a sustained systolic BP of 130 mmHg or higher and sets a treatment target of <130/80 mmHg for most adults [7].

First-line antihypertensives

The four preferred first-line classes for most patients are:

1. Thiazide diuretics (chlorthalidone 12.5-25 mg preferred over hydrochlorothiazide based on ALLHAT data)
2. ACE inhibitors (lisinopril 10-40 mg) or ARBs (losartan 50-100 mg) for patients with diabetes or CKD
3. Calcium channel blockers (amlodipine 5-10 mg) for older adults and those with isolated systolic hypertension
4. Beta-blockers reserved for patients with heart failure with reduced ejection fraction (HFrEF) or post-MI [7]

ALLHAT (N=33,357) found chlorthalidone superior to amlodipine and lisinopril for preventing heart failure [8], making it the preferred thiazide in most guidelines.

SPRINT trial and the case for <120 mmHg

SPRINT (N=9,361) randomized non-diabetic adults with elevated CV risk to a systolic target of <120 mmHg vs. <140 mmHg. The intensive arm cut the composite of MI, ACS, stroke, HF, and CV death by 25 percent (P<0.001) and reduced all-cause mortality by 27 percent [9]. These findings pushed many clinicians toward lower targets in high-risk patients, though shared decision-making around side effects (hypotension, AKI) is required. Note: SPRINT excluded patients with diabetes; separate guidance applies to that group.

SGLT2 Inhibitors: Beyond Diabetes

SGLT2 inhibitors were approved for type 2 diabetes but have since earned dedicated CV indications. EMPA-REG OUTCOME (N=7,020) showed empagliflozin (Jardiance) 10-25 mg cut the three-point MACE composite by 14 percent and CV death specifically by 38 percent versus placebo [10]. CANVAS (N=10,142) replicated this pattern with canagliflozin [11].

Heart failure and kidney protection

DAPA-HF (N=4,744) showed dapagliflozin (Farxiga) 10 mg reduced the composite of worsening HF or CV death by 26 percent in HFrEF patients regardless of diabetes status [12]. EMPEROR-Reduced confirmed a similar signal for empagliflozin in HFrEF. The 2022 AHA/ACC Heart Failure guideline gives SGLT2 inhibitors a Class I, Level A recommendation for HFrEF [13].

Who benefits most?

Patients with established T2D and high ASCVD risk, HFrEF with or without diabetes, or CKD with albuminuria above 300 mg/g see the largest absolute benefit. The FDA approved dapagliflozin for CKD in 2021 based on DAPA-CKD (N=4,304), which showed a 39 percent relative risk reduction in the composite of sustained eGFR decline, ESRD, or kidney or CV death [14].

GLP-1 Receptor Agonists: Weight, Glucose, and the Heart

GLP-1 receptor agonists lower blood glucose, promote weight loss, and independently cut CV events in high-risk patients. LEADER (N=9,340) showed liraglutide 1.8 mg cut MACE by 13 percent in T2D patients with high CV risk [15]. Semaglutide's signal is stronger.

SELECT trial: CV benefit independent of diabetes

SELECT (N=17,604) enrolled non-diabetic adults with BMI ≥27 and established CVD. Weekly semaglutide 2.4 mg (Wegovy) cut non-fatal MI, non-fatal stroke, and CV death by 20 percent over a mean follow-up of 33.6 months [16]. This was the first large-scale cardiovascular outcomes trial to demonstrate MACE reduction in people without diabetes, extending the indication well beyond glucose control.

Practical considerations for GLP-1 use in CV prevention

The table below summarizes a practical decision framework for choosing between an SGLT2 inhibitor and a GLP-1 agonist when both are theoretically appropriate.

| Clinical Feature | Favor SGLT2 Inhibitor | Favor GLP-1 Agonist | |---|---|---| | Primary concern | HFrEF or CKD | Obesity-driven ASCVD risk | | Weight loss needed | Modest (2-3 kg typical) | Substantial (10-15% of body weight) | | GI tolerability | Generally good | Nausea in 15-40% initially | | Injection aversion | Oral daily pill | Weekly subcutaneous injection | | eGFR | Avoid if <20 mL/min/1.73m² | No eGFR restriction | | Established CVD without diabetes | Limited data | SELECT supports use |

Clinicians at HealthRX follow a "cardiometabolic phenotyping" approach: patients with HFrEF or significant proteinuria receive the SGLT2 inhibitor first; patients with BMI ≥30 and established ASCVD but preserved cardiac function receive the GLP-1 agonist first; and patients with both phenotypes may receive both agents concurrently per shared decision-making.

Aspirin in Primary Prevention: A Significant Reversal

Aspirin was standard for primary prevention for decades. Three large trials published between 2018 and 2019 (ARRIVE, ASPREE, ASCEND) changed that consensus dramatically. ASPREE (N=19,114) found that aspirin 100 mg daily in healthy adults ≥70 years increased major hemorrhagic events without reducing MACE [17].

The USPSTF 2022 update recommends against initiating aspirin for primary prevention in adults aged 60 and older and assigns only a "C" recommendation (individualized decision) for adults aged 40 to 59 with a 10-year ASCVD risk ≥10 percent [18]. Aspirin remains standard of care for secondary prevention (established CVD) at 75-100 mg daily.

Lifestyle Modification: The Evidence Is Stronger Than Many Assume

Lifestyle change is not a soft recommendation. PREDIMED (N=7,447) randomized adults at high CV risk to a Mediterranean diet supplemented with extra-virgin olive oil, a Mediterranean diet supplemented with mixed nuts, or a control low-fat diet. The Mediterranean-diet groups cut MACE by approximately 30 percent [19]. That magnitude rivals moderate-intensity statin therapy in primary prevention populations.

Diet, exercise, and smoking

• Diet: Mediterranean or DASH pattern. Target ≥5 servings of fruits and vegetables daily, ≥2 servings of fish weekly, and replacement of saturated fat with mono- and polyunsaturated fat [19].
• Physical activity: The 2018 Physical Activity Guidelines for Americans specify ≥150 minutes of moderate-intensity or ≥75 minutes of vigorous-intensity aerobic activity per week [20]. Each 10 MET-hours/week increase is associated with approximately 20 percent lower CV mortality.
• Smoking cessation: Smoking doubles ASCVD risk. Cessation returns risk toward baseline within 1 to 3 years for most vascular endpoints. Varenicline (Chantix/Champix) increases 6-month quit rates to approximately 33 percent vs. 12 percent with placebo [21].

Weight management targets

A 5 to 10 percent reduction in body weight improves BP, LDL-C, triglycerides, and glycemic control simultaneously. Weight loss of ≥15 percent achieves near-complete glycemic remission in many patients with T2D, per the DiRECT trial (N=298) [22].

Monitoring After Starting CV Prevention Therapy

Lipid monitoring schedule

• Baseline fasting lipid panel before initiating statin therapy.
• Repeat at 4 to 12 weeks after starting or changing therapy to confirm response.
• Once at goal, measure LDL-C every 3 to 12 months depending on adherence concern [1].

Blood pressure monitoring

Home blood pressure monitoring (HBPM) with a validated cuff reduces white-coat effect and provides more prognostically relevant readings than office BP. SPRINT used automated office BP; its targets may not translate directly to casual-cuff measurements. The 2017 ACC/AHA guideline recommends confirming hypertension with 2 or more readings on 2 or more occasions [7].

Glucose and kidney function with SGLT2 inhibitors

• HbA1c every 3 months until stable, then every 6 months.
• eGFR and serum creatinine at baseline, at 2 to 4 weeks after initiation, then annually.
• Hold SGLT2 inhibitors 3 days before elective surgery to reduce euglycemic DKA risk.

Who Should Not Use These Therapies?

Statin contraindications and cautions

Statins are contraindicated in pregnancy (FDA category X). Patients with active liver disease, unexplained persistent elevations in transaminases (>3x ULN), or a prior severe statin-induced myopathy should avoid statin therapy or use only under specialist supervision [6].

SGLT2 inhibitor contraindications

Do not use in type 1 diabetes (high DKA risk), eGFR <20 mL/min/1.73m² (limited efficacy and potential harm), or in patients with recurrent urinary tract infections or genital mycotic infections that are poorly controlled.

GLP-1 agonist contraindications

GLP-1 agonists are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN 2 syndrome (based on rodent carcinogenicity data, though causality in humans is not established). They should be used with caution in patients with a history of pancreatitis [15].

Aspirin cautions

Active peptic ulcer disease, allergy to NSAIDs, or inherited bleeding disorders are contraindications to aspirin for either primary or secondary prevention. Concomitant anticoagulant use dramatically increases hemorrhagic risk.

Comparison Table: CV Prevention Medications at a Glance

| Drug Class | Example Agent | LDL-C Reduction | MACE Reduction | Key Trial | Primary Indication | |---|---|---|---|---|---| | High-intensity statin | Atorvastatin 80 mg | ~50% | ~22% per 1 mmol/L LDL-C | CTT meta-analysis | Dyslipidemia / ASCVD | | Ezetimibe add-on | Ezetimibe 10 mg | Additional 15-20% | 6.4% additional RRR | IMPROVE-IT | Statin-insufficient LDL control | | PCSK9 inhibitor | Evolocumab 140 mg Q2W | 50-60% additional | 15% RRR | FOURIER | Very-high-risk, statin-maximized | | SGLT2 inhibitor | Empagliflozin 10 mg | Neutral | 14% MACE; 38% CV death | EMPA-REG OUTCOME | T2D + ASCVD; HFrEF; CKD | | GLP-1 agonist | Semaglutide 2.4 mg SC | Neutral | 20% MACE | SELECT | Obesity + ASCVD (with or without T2D) | | Antihypertensive | Chlorthalidone 25 mg | Neutral | 25% composite (SPRINT) | SPRINT / ALLHAT | Hypertension | | Aspirin | Aspirin 81 mg | Neutral | Benefit only in secondary prevention | ARRIVE / ASPREE | Secondary prevention only |

Putting It All Together: A Risk-Stratified Approach

A 58-year-old man with T2D, BMI 34, LDL-C 118 mg/dL, BP 138/86 mmHg, and a 10-year PCE score of 18 percent (high risk, not yet established CVD) would, under 2026 standard of care, receive:

1. Atorvastatin 40-80 mg (LDL-C target <70 mg/dL)
2. Lisinopril 10-20 mg titrated toward BP <130/80 mmHg
3. Empagliflozin 10 mg (SGLT2 inhibitor for T2D + high ASCVD risk)
4. Consider semaglutide 1.0-2.4 mg weekly if weight loss ≥10% is needed to reach additional metabolic targets
5. Mediterranean-pattern diet counseling and 150 minutes per week aerobic exercise prescription
6. No aspirin unless he sustains a qualifying CV event

The ACC/AHA 2019 primary prevention guideline states: "For adults 40-75 years of age with LDL-C ≥70 mg/dL and a 10-year ASCVD risk of ≥7.5%, clinicians and patients should engage in a risk discussion before starting statin therapy" [1]. That shared decision-making principle runs through every layer of the framework above.